Comparison · NCT01912716-e387f5e9
Standard 100mg Dose vs High Dose 200 mg: Number of Participants Who Developed Post-ERCP Pancreatitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard 100mg Dose vs High Dose 200 mg: Number of Participants Who Developed Post-ERCP Pancreatitis. Trial comparisons, record NCT01912716-e387f5e9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01912716-e387f5e9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.12 | 0.181 | wilson | |
| Risk in group 2 | 0.125 | 0.0989 | 0.156 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0231 | -0.0188 | 0.065 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.19 | 0.871 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.853 | 1.74 | log | |
| Number needed to treat, for one more participant with the outcome on Standard 100mg Dose than on High Dose 200 mg | 43.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard 100mg Dose | patients receiving 100mg indomethacin | 76 | 515 | OG000 |
| Group 2 | High Dose 200 mg | patients receiving 200mg indomethacin | 65 | 522 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Developed Post-ERCP Pancreatitis
- Description
Assessment of whether patients developed post-ERCP pancreatitis, defined as a new onset of pain (or worsening of existing pain) in the upper abdomen, an elevation in pancreatic enzymes of at least three times the upper limit of the normal range 24 hours after the procedure, and hospitalization for at least two nights.
- Time frame
- 5 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
- NCT number
- NCT01912716
- Phases
- PHASE2, PHASE3
- Conditions
- Post-ERCP Pancreatitis
- Interventions
- high dose indomethacin, standard dose indomethacin
- Lead sponsor
- Indiana University
- Results first posted
- 2019-06-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01912716?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01912716-e387f5e9